The Phase III VOLGA trial has reached its primary endpoints, proving that the Imfinzi EV bladder cancer combination delivers historic survival gains in the perioperative setting.
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
In a potentially practice-changing development for oncology, Merck announced that its Phase 3 KEYNOTE-B15 trial (also known as EV-304) has met its primary and key [Read More…]
The combination of PADCEV and KEYTRUDA has shown a significant improvement in both event-free survival and overall survival for patients with muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy.
